Estrana

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estrana

Estrana: Defining the Hormone Replacement Therapy Agent

Estrana is a prescription pharmaceutical preparation classified as an estrogen within the therapeutic category of Hormone Replacement Therapy (HRT) or Estrogen Replacement Therapy (ERT). As a single-agent product, its primary purpose is to address systemic deficits of the essential female sex hormone. Its pharmacological classification identifies it as a potent estrogenic agent.

The medication functions as an estrogen receptor agonist, meaning it activates the body’s cellular receptors in the same manner as natural estrogen. This restoration of the steroid hormone level is intended to maintain physiological balance and address issues related to hormonal decline and systemic deficiency.

Composition and Origin: The Bio-identical Estradiol

The sole active ingredient in Estrana is estradiol, which is chemically and biologically identical to the naturally occurring primary human estrogen, 17beta-Estradiol, making it a bio-identical compound. Although commercially manufactured for pharmaceutical purity, the active molecule mimics the hormone produced naturally by the human body.

The estradiol compound is formulated into various dosage forms for systemic delivery to individuals experiencing low estrogen levels. These forms, which include oral tablets, transdermal patches, and gels, allow for different routes of administration—whether oral or transdermal—depending on the specific therapeutic requirements.

Primary Function: Addressing Estrogen Deficiency

The fundamental role of Estrana is hormone restoration, providing a systemic supply of estrogen to alleviate the effects associated with a lack of this hormone. By supplying the necessary compound, the medication aims to correct the core issue of estrogen deficiency, which commonly arises during menopause or following surgical procedures such as an ovariectomy. This hormonal action supports the body's estrogen-dependent processes, providing a stabilizing effect aimed at regulating hormonal levels.

Regulatory References

  1. Estrogen: MedlinePlus Drug Information

What side effects are possible with Estrana?

Possible Side Effects and Safety Information

The use of Estrana is associated with a range of possible side effects, with some involving serious health risks that warrant careful consideration and monitoring. Government regulatory bodies have issued warnings regarding the potential for serious adverse reactions, which include cardiovascular disorders, certain malignant neoplasms, and probable dementia.

Serious and Clinically Significant Adverse Reactions

The most significant safety concerns include an increased risk of endometrial cancer (cancer of the uterus lining), especially in women who still have a uterus and are not taking a progestin. Other serious risks involve cardiovascular events, such as stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI). Additionally, studies have shown an increased risk of breast cancer and an increased risk of probable dementia in postmenopausal women 65 years of age and older.

Estrana is typically contraindicated (should not be used) in individuals with a history of or active DVT, PE, stroke, MI, certain cancers (including breast or known estrogen-dependent neoplasia), known liver disease, or undiagnosed abnormal genital bleeding.

Common Adverse Reactions

The most frequently reported side effects observed in clinical trials, occurring in 5% or more of patients, are generally non-serious and involve systemic and localized reactions. These include headache, breast tenderness, nausea, back pain, and nasopharyngitis.

Population-Specific Safety Notes

For women who have a uterus, a progestin must be prescribed alongside Estrana to mitigate the risk of developing endometrial hyperplasia and cancer. Treatment is recommended to be initiated at the lowest effective dosage for the shortest duration consistent with the therapeutic goal.

Overdose and Emergency Response

The official regulatory documentation for estradiol (Estrana) defines the overdose profile primarily by predictable clinical signs that require immediate professional attention. Acute overexposure is generally characterized by gastrointestinal distress, including nausea and vomiting. The most notable sign is often vaginal bleeding, specifically withdrawal bleeding, which occurs following the excessive hormonal exposure.

Other documented clinical signs may include breast tenderness, fluid retention, headache, and drowsiness. No acute, life-threatening systemic effects are typically listed in the regulatory overdose sections as direct manifestations of acute overexposure.

When to Seek Immediate Medical Help

Regulatory authorities mandate that emergency medical attention must be sought right away upon suspicion of an overdose. Contacting a poison control center or emergency services is the required immediate action, as stated in the official prescribing information.

Official Management and Monitoring

Since no specific antidote is documented for estradiol overdosage, management is defined as symptomatic and supportive treatment. Clinical procedures documented in regulatory guidance for overdose situations include:

  • Continuous monitoring of vital signs (temperature, pulse, blood pressure) by healthcare personnel.
  • Performing necessary blood and urine tests for evaluation.
  • Administration of activated charcoal or Intravenous (IV) fluids in specific, severe cases.

This official profile emphasizes the need for professional monitoring and supportive care when dealing with overexposure.

Therapeutic Uses of Estrana

What Estrana Treats: Main Uses and Benefits

The primary therapeutic role of Estrana is to help manage the disruptive systemic symptoms associated with estrogen deficiency. It is applied across domains where additional symptomatic support is needed, primarily for managing moderate to severe vasomotor symptoms (such as hot flashes and night sweats), addressing Genitourinary Syndrome of Menopause (GSM) symptoms, and for the prevention of postmenopausal osteoporosis in high-risk patients.

The therapy is relevant when supportive symptom management is needed, as it contributes to improved comfort during periods of heightened physiological activity and contributes to easing the overall symptom load. It is used in clinical settings that involve acute or unstable symptom patterns stemming from primary hormone deficiency, such as following surgical castration or in cases of ovarian failure.

Contextual Note: Management of Vasomotor Symptoms

Estrana is applied in scenarios where hot flashes and night sweats become more noticeable, offering symptomatic relief and providing support that helps patients cope with these fluctuations.

“It is commonly used to help manage symptoms related to physical discomfort, providing support that may assist with comfort during symptomatic periods.”

Regulatory References

  1. Official FDA Label on DailyMed

Eligibility and Restrictions for Use

Eligibility and Contraindications for Estrana

Estrana is an estrogen preparation approved for use primarily in postmenopausal women to address systemic estrogen deficiency. Eligibility is strictly defined by regulatory documents, listing several conditions under which the medicine must not be used.

Absolute Contraindications

Estrana is contraindicated in patients with:

  • A known or suspected history of estrogen-dependent cancer (e.g., breast cancer).
  • Active or a history of arterial or venous thromboembolic disease (e.g., stroke, myocardial infarction, deep vein thrombosis, or pulmonary embolism).
  • Undiagnosed abnormal genital bleeding.
  • Known thrombophilic disorders or active liver disease.
  • Known or suspected pregnancy.

Population Restrictions and Cautions

  • Uterine Status: Women with an intact uterus are required by labeling to use Estrana in combination with a progestogen to reduce the risk of endometrial cancer.
  • Age: Use in the pediatric population is not indicated and not established. Caution is required when prescribing to women aged 65 and older.
  • Physiological State: The medicine is not recommended for use by nursing mothers. Use requires caution in patients with existing renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Estrana (Estradiol) is defined primarily by its pharmacokinetic clearance, which involves partial metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This means that co-administration with certain agents that modify the activity of this enzyme can formally alter the resulting plasma concentration of Estradiol.

Documented Exposure-Modifying Agents

Substances that Increase Estradiol Concentration

Agents classified as CYP3A4 inhibitors are documented to increase the concentration of Estradiol. Specific medicines include the antibiotics Erythromycin and Clarithromycin, the antifungals Ketoconazole and Itraconazole, and the antiviral Ritonavir. Consumption of Grapefruit juice is also documented as acting as a CYP3A4 inhibitor.

Substances that Reduce Estradiol Concentration

Conversely, co-administration with strong CYP3A4 inducers may reduce Estradiol plasma concentrations. Officially listed pharmaceutical inducers include the anticonvulsants Phenobarbital and Carbamazepine, and the antibiotic Rifampin. The herbal supplement St. John's Wort preparations (Hypericum perforatum) is also documented as a CYP3A4 inducer that may reduce Estradiol exposure.

No medicinal products are officially listed as strictly contraindicated combinations, and no mandatory timing-based separation rules are documented in the regulatory labeling.

Mechanism of Action

How Estrana Works at the Biological Level

Dual Modulation of Serotonin and Noradrenaline Systems

Estrana's primary mechanism involves the simultaneous modulation of central 5-HT1A and alpha-2 adrenergic (alpha2-AR) receptors. The compound acts as a partial agonist at 5-HT1A autoreceptors and functions as an antagonist at presynaptic alpha2-AR. This dual targeting engages mechanisms that influence the release and signaling kinetics of both serotonin (5-HT) and noradrenaline (NE), resulting in modified synaptic signaling dynamics for these two neurotransmitters.

Cascade for Enhanced Monoamine Transmission

The alpha2-AR antagonism initiates a cascade by removing the inhibitory brake on noradrenaline neurons, promoting increased NE release. Concurrently, the 5-HT1A partial agonism and subsequent receptor desensitization leads to an enhanced level of synaptic serotonin transmission in target regions. This process modifies early molecular steps over time to achieve a time-dependent enhancement of monoamine transmission, which influences the systemic neurochemical outcomes.

Modification of Central Neuroendocrine Systems

Altered concentrations of serotonin and noradrenaline in the limbic and cortical regions modify signaling within key neural circuits, including the hypothalamic-pituitary-adrenal (HPA) axis. This activity in targeted neural pathways leads to altered neurochemical processing, resulting in changes in downstream physiological response patterns associated with central regulation.

Dosage and Administration Information

Estrana is an estrogen preparation available in multiple forms to allow for flexibility in administration, including oral tablets, transdermal patches, topical gels, and intravaginal products. The specific formulation determines the route of delivery.

Dosing regimens commonly involve oral tablets dosed in the range of 0.5 mg to 2 mg once daily. Transdermal systems are available in strengths ranging from 0.025 mg/day up to 0.1 mg/day, with patches applied either once weekly or twice weekly depending on the specific product. Standard practice involves employing the lowest effective dose for the shortest duration consistent with treatment goals, with periodic assessments to taper or discontinue the medicine (e.g., every three to six months).


Contextual instructions for proper use vary by form. Oral tablets may be taken with or without food. In contrast, transdermal patches are applied to a clean, dry area on the lower abdomen or buttocks, and topical gels require adequate drying time before clothing covers the application site. Regarding schedule adherence, if a dose is missed, it should be administered as soon as possible, but a double or extra dose must be strictly avoided. For patients with an intact uterus, a progestogen is co-administered for part of the cycle as part of the standard therapeutic approach. The safety and efficacy for use in pediatric populations are not established.

Recent Clinical Evidence

Research evidence / Overview of studies for Estrana


Evidence for use in Vasomotor Symptoms (Hot Flashes and Night Sweats)

Estrana was evaluated in the research context to explore the outcomes related to moderate to severe hot flashes and night sweats, which are outcomes related to physical discomfort. The primary evidence base for this application is largely composed of short-term Randomized Controlled Trials (RCTs). These studies explored periods of increased symptom activity and aimed to track how symptoms change over time in observed groups compared to those using an inactive substance (placebo).

Researchers primarily monitored patient-reported outcomes describing perceived discomfort, focusing on the frequency and severity of hot flashes. Findings reported measured changes in the average number of hot flashes per day over the study period, which often spanned just 4 to 12 weeks. While many studies describe short-term changes in symptoms, long-term outcomes are not fully established regarding the maintenance of symptom control over multiple years.


Research Evidence Exploring Postmenopausal Osteoporosis Prevention

Evidence was evaluated in studies exploring large-scale, long-term Randomized Controlled Trials (RCTs) and extended Observational Studies. Research exploring Estrana's effect on bone health focuses primarily on the prevention of postmenopausal osteoporosis, a condition marked by functional limitations and a risk of fracture.

The studies primarily examined changes in Bone Mineral Density (BMD) at the hip and spine. Research also monitored the long-term incidence of vertebral and non-vertebral fractures. For bone health, the research scenarios include long follow-up durations, where data suggest patterns related to fracture incidence over periods of five to seven years or more. A key research limitation is that the results apply only to the populations studied.


Evidence for use in Genitourinary Symptoms of Menopause (GSM)

Estrana was studied for research exploring Genitourinary Syndrome of Menopause (GSM), which involves outcomes linked to inflammatory or irritative states. Research included Randomized Controlled Trials (RCTs) and Systematic Reviews. The trials examined patient-reported outcomes describing perceived discomfort, such as vulvovaginal dryness and pain during sex (dyspareunia).

A point of uncertainty is that a significant portion of high-quality data originates from studies on locally applied, low-dose estradiol formulations. Therefore, while systemic therapy is studied for this indication, certainty remains low regarding the long-term impact of systemic Estrana on objective tissue health markers beyond the initial short study periods.


Research Gaps and What Remains Uncertain About Estrana

The evidence landscape for Estrana contains several documented limitations and gaps. One area of uncertainty relates to the comparative evidence: robust, head-to-head RCTs are limited when attempting to definitively compare the measured outcomes of the oral tablet versus the transdermal patch or gel over extended periods.

Another limitation is that the follow-up durations were often short in the primary efficacy studies for symptom control (like hot flashes), meaning the long-term effects are not fully established beyond the initial assessment periods. Research is ongoing to address these gaps and further refine the understanding of observed symptom patterns across all relevant subgroups.

Key Studies & References

  1. DailyMed: Estradiol (Estrana) Oral Tablet Official FDA-Approved Labeling

Frequently Asked Questions (FAQ)

Common questions about Estrana (FAQ)

Q: Is it mandatory to take Estrana with food?

Official product information indicates that Estrana oral tablets may be taken with or without food. For other forms of the medication, such as transdermal patches or topical gels, they are applied externally and do not have any requirements related to food consumption.

Q: How should Estrana be used if I miss a dose?

Official guidance suggests that if a dose of Estrana is missed, its administration should occur as soon as possible. However, regulatory instructions caution against taking a double or extra dose, even if the timing is close to your next scheduled administration time.

Q: Can Estrana be crushed or cut?

The ability to alter Estrana tablets, such as crushing or cutting them, is dependent on the specific design of the pill. If a tablet is not scored, regulatory guidance typically recommends that it be taken whole to ensure the medicine works as intended and is absorbed correctly.

Q: Do I need to change my diet while taking Estrana?

The official documentation mentions a specific diet-related interaction: grapefruit juice. This component is mentioned as it may increase the concentration of the medication in your body. No other general diet changes are strictly advised in the official documentation.

Q: What if I'm taking herbal remedies with Estrana?

Official documents specifically list St. John's Wort preparations as an herbal remedy that can potentially reduce the amount of Estradiol in the bloodstream. Official guidance indicates the importance of reporting all herbal remedies and supplements to a healthcare provider.

Q: Does Estrana interact with birth control pills?

Estrana is an estrogen product. Official guidelines generally caution against combining multiple hormone sources, such as hormonal birth control pills, as this may be associated with an increased risk of serious side effects.

Q: Does Estrana need to be taken long-term?

Regulatory documents state that Estrana is generally recommended at the lowest effective dose for the shortest duration consistent with treatment goals. Official guidance suggests that attempts to taper or discontinue the medicine should occur at regular intervals (e.g., every three to six months).

Q: What are the most common side effects people mention about Estrana?

Official data from clinical trials describes the most common side effects as those occurring in five percent or more of patients. These generally include headache, breast tenderness, nausea, back pain, and nasopharyngitis.

Q: Is Estrana available as a generic version?

The active ingredient in Estrana, estradiol, is widely available in generic versions for various dosage forms, including oral tablets and transdermal patches.

Q: Can Estrana be taken by people with kidney issues?

Regulatory labeling advises that caution is required when prescribing Estrana to patients who have existing renal (kidney) impairment.

Q: Do older adults react differently to Estrana?

Official labeling advises caution when prescribing Estrana to women aged 65 and older. Studies have examined this population and indicate an increased risk of probable dementia in postmenopausal women in this age group.

Q: What happens if I stop taking Estrana suddenly?

Regulatory information suggests that attempts to taper or discontinue the medicine should occur at regular intervals. When treatment is stopped, the symptoms Estrana was prescribed for may return.

Q: Is it normal to feel [mild, common side effect] when starting Estrana?

When beginning treatment with Estrana, it is possible to experience the most frequently reported side effects observed in clinical trials. These common effects include headache, breast tenderness, nausea, back pain, and nasopharyngitis.

Q: What is the average time it takes for Estrana to be fully removed from the body?

The active ingredient in Estrana, estradiol, has a short elimination half-life. This means that the concentration of the medication tends to decrease relatively quickly once use is stopped or a transdermal system is removed.

Q: Is Estrana a controlled substance?

Estrana contains the active ingredient estradiol, which is an estrogen product. It is not classified as a federally controlled substance by regulatory bodies.

Q: Do different strengths of Estrana have different side effects?

Official documents indicate that some common side effects, such as breast tenderness, have been described as potentially dose-dependent. This suggests they may be more noticeable with higher strengths of the medication.

Q: Can Estrana cause changes in mood or sleep?

Official adverse reaction data includes changes in mood. Specifically, depression has been listed as a less common adverse reaction associated with Estrana in clinical trials.

Q: Is Estrana approved in countries outside of the US?

Official documents from numerous international regulatory bodies, including the European Medicines Agency (EMA) and the UK's MHRA, address the use and safety of estradiol products.

Q: Are there specific food interactions to be aware of when taking Estrana?

The official labeling documents one specific diet-related interaction: grapefruit juice. This is the only specific food component addressed, and it is mentioned because it may increase the concentration of estradiol in the body.

Q: Does Estrana have a rebound effect when stopped?

Regulatory information suggests that attempts to taper or discontinue the medicine should occur gradually. When treatment is stopped, the symptoms Estrana was prescribed to treat may return.

Q: What is the typical monitoring process for patients taking Estrana?

Due to the potential for serious adverse reactions, regulatory documents advise careful consideration and monitoring. For women with an intact uterus, this includes co-administering a progestogen to mitigate the risk of endometrial cancer.

Q: Can Estrana affect blood sugar levels?

Official labeling indicates that Estradiol may interfere with blood glucose control. This suggests that monitoring may be needed for patients taking diabetic medications.

How should Estrana be stored and disposed of?

Official Storage and Disposal Requirements

To ensure Estrana's stability and effectiveness, the medication must be stored according to official regulatory requirements, which typically align with controlled room temperature.

Storage Conditions:

  • Temperature: Store at controlled room temperature, usually between 20 C and 25 C (68 F and 77 F).
  • Handling: Do not refrigerate or freeze the product. Protection from excessive heat, moisture, and light is required.
  • Packaging: Keep the medication in its original container, tightly closed, to maintain product integrity.
  • Safety: Always store Estrana out of the sight and reach of children.

Disposal Instructions:

Unused or expired Estrana should be disposed of properly to prevent accidental exposure or environmental contamination. The best method is to return the medication through a community drug take-back program. If a program is unavailable, mix the product with an undesirable substance (such as used coffee grounds), place it in a sealed bag, and discard it in the household trash. Do not flush Estrana down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estrana found in:

A-Z Index: